IMUX MEXC RealStocks
Own real IMUX shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-12 20:39:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Immunic, Inc. (IMUX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $7.80, with a market capitalization of $109.70M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.06 to $17.43. This page covers its latest market performance, valuation, price trends and company information.
$109.70M | |
$7.95 | |
$8.34 | |
$7.53 | |
$8.12 | |
157.01K | |
341.27K | |
-- | |
$17.43 | |
$5.06 | |
-- | |
-- |
Immunic, Inc. (IMUX) is currently trading at $7.80 as of 2026-11-12 20:37:00, down 3.02% ($0.24) from the previous close of $8.12
During today's regular trading session, IMUX has traded between $7.53 and $8.34, with a trading volume of 157.01K shares. The current price is near the middle of today's range.
Over the past seven days, Immunic, Inc. (IMUX) moved from $7.60 to $7.80, representing a gain of 2.68% ($0.20).
The stock traded between $7.21 and $8.42 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 200.26 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 22.2%
IMUX is currently trading at $7.80, placing it 22.2% of the way from its 52-week low of $5.06 to its 52-week high of $17.43. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 95 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Immunic, Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Immunic, Inc. (IMUX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to IMUX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between IMUX shares and USD.
IMUX Shares to USD
1.00 IMUX shares = 7.804 USD
Calculations are estimates based on the latest available price and are for reference only.